CX Institutional
RVMD icon

CX Institutional’s Revolution Medicines RVMD Stock Holding History

CX Institutional’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27K Hold
132
– – ﹤0.01% 1166
2026
Q2 		$25K Buy
132
+27
+26% +$3.94K ﹤0.01% 1125
2026
Q1 		$10K Buy
+105
New +$10.6K ﹤0.01% 1304

Other funds holding RVMD

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Loftus Peak Pty Ltd
Loftus Peak Pty Ltd Sydney, Australia $781M AUM
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

CX Institutional's RVMD Position: Q3 2026 in Review

CX Institutional held its Revolution Medicines (RVMD) position steady in Q3 2026 at 132 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #1166.

CX Institutional first reported a position in RVMD in Q1 2026 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • CX Institutional held 132 shares of Revolution Medicines worth $27K as of Q3 2026.
  • CX Institutional left its Revolution Medicines share count unchanged in Q3 2026.
  • Revolution Medicines made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1166 holding.
  • CX Institutional first reported a position in Revolution Medicines in Q1 2026 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.